GlassScriptPhysician profile
Emily D Hanson
NPI 1023083748
$7,136.01
in general payments reported to CMS, 2019-2025
38 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,173 · 2020: $233 · 2021: $62.75 · 2022: $994 · 2023: $1,761 · 2024: $1,260 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,673.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $975.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $954.17 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $854.65 | 2019-2025 | |
| Glaxosmithkline, LLC. | $544.29 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $416.15 | 2019-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $298.62 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.08 | 2019-2025 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $244.67 | 2019-2025 | Spravato |
| Pfizer INC. | $228.39 | 2019-2025 | |
| Novo Nordisk INC | $219.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $216.95 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $190.44 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3, Freestyle Libre |
| Astellas Pharma US INC | $175.19 | 2020-2025 | Veozah, Mycamine, Myrbetriq |
| Sumitomo Pharma America, INC. | $174.73 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $135.89 | 2022-2023 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.